AbbVie

News

FDA fast-tracks AbbVie's spinal injury drug

The FDA has fast tracked development of AbbVie’s potential spinal injury drug, elezanumab, a process that will be aided by digital analysis.

News

A healthy discussion on funding tomorrow’s treatments

Despite biosims, ulcerative colitis drugs still cost too muc...

None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough to be cost-effective, says the Institute for Clinical and Economic Review

News

AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cance...

AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record licensing deal involving a Chinese biotech.

News

Gilead eyes takeover of cancer biotech Tizona, despite its t...

Gilead Sciences’ run of oncology-focused deals has continued with an option to buy cancer immunotherapy specialist Tizona – even though the biotech’s lead drug candidate is alr

News

J&J's Tremfya to join crowded psoriatic arthritis market aft...

The FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 class to gain a foothold in this indication.

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

After Celgene deal, BMS shoots up pharma market cap rankings

Bristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies by market cap into the top 10, according to a new analysis by GlobalDat

FDA fast-tracks AbbVie's spinal injury drug

Despite biosims, ulcerative colitis drugs still cost too muc...

AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cance...

Gilead eyes takeover of cancer biotech Tizona, despite its t...

J&J's Tremfya to join crowded psoriatic arthritis market aft...

After Celgene deal, BMS shoots up pharma market cap rankings

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks